Competing interests
M.S.R. is currently employed by Heidelberg University Hospital and reports research funding from Bristol Myers Squibb, Janssen and Heidelberg Pharma; consultancy for Bristol Myers Squibb, Amgen, GlaxoSmithKline, Janssen, Sanofi, Pfizer, AbbVie, Oncopeptides and Takeda; honoraria from Bristol Myers Squibb, Amgen, GlaxoSmithKline, Janssen, Sanofi, Pfizer, AbbVie and Oncopeptides; membership on an entity’s board of directors or advisory committees for Janssen, Amgen, Bristol Myers Squibb, Sanofi, AbbVie and GlaxoSmithKline; and travel expenses from Bristol Myers Squibb, Amgen, Janssen, Sanofi, AbbVie and Oncopeptides. N.W. is funded by the Advanced Medical Scientist Program of Heidelberg University, Faculty of Medicine, and reports research funding from The Binding Site, Sanofi-Aventis and Bristol Myers Squibb/Celgene; honoraria from Sanofi-Aventis; and membership on an entity’s board of directors or advisory committees for Sanofi-Aventis and GlaxoSmithKline. K.M.K. is currently employed by University Hospital Wurzburg and reports honoraria from AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sanofi, Takeda and Stemline Therapeutics and consultancy for AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sanofi, Takeda and Stemline Therapeutics. J. Krönke is currently employed by Charité – Universitätsmedizin Berlin and reports consultancy for Janssen, Takeda, AbbVie, Jazz Pharmaceuticals, Sanofi, AstraZeneca and Pfizer; honoraria from Janssen, Takeda, AbbVie, Jazz Pharmaceuticals, Sanofi, AstraZeneca and Pfizer; and speakers bureau for Janssen, Takeda, AbbVie, Jazz Pharmaceuticals, Sanofi, AstraZeneca and Pfizer. R.F. reports honoraria from Pfizer, Sanofi, Takeda, Janssen, Bristol Myers Squibb/Celgene and Amgen and travel expenses from Janssen, GlaxoSmithKline and Bristol Myers Squibb/Celgene. K.W. reports consultancy for Bristol Myers Squibb/Celgene, Sanofi, GlaxoSmithKline, Pfizer, Menarini, Janssen, Adaptive Biotechnologies, Amgen, Roche, BeiGene, Oncopeptides, Karyopharma, Takeda and Regeneron; honoraria from Bristol Myers Squibb/Celgene, Sanofi, GlaxoSmithKline, Pfizer, Menarini, Janssen, Adaptive Biotechnologies, Amgen, Roche, AstraZeneca, BeiGene, Oncopeptides, Karyopharma, Novartis, Stemline Therapeutics and Takeda; and research grants to institution from Bristol Myers Squibb/Celgene, Sanofi, GlaxoSmithKline, Janssen, Amgen and AbbVie. L.P. is employed by the University Clinic Heidelberg. L.P. has no conflicts of interest to report. U.B. has no conflicts of interest to report. A.B. has no conflicts of interest to report. J.M. reports serving in an advisory role for Johnson & Johnson and Pfizer and receiving honoraria from Johnson & Johnson, Sanofi, Pfizer and Skyline Dx. S.H. has no conflicts of interest to report. R.A. has no conflicts of interest to report. M. Hundemer reports research funding from Novartis, Janssen, Sanofi, Bristol Myers Squibb/Celgene, Alexion and Roche; membership on an entity’s board of directors or advisory committees for Becton Dickinson and BeiGene; and travel expenses from BeiGene and Bristol Myers Squibb/Celgene. S.R.B. reports honoraria and consultation fees from Johnson & Johnson, Pfizer, Sanofi, Takeda and GlaxoSmithKline. E.K.M. reports serving in a consulting or advisory role for Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Oncopeptides, Pfizer, Sanofi, Stemline Therapeutics and Takeda; honoraria from Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Oncopeptides, Pfizer, Sanofi, Stemline Therapeutics and Takeda; research funding from Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi and Takeda; and travel accommodations and expenses from Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Sanofi, Stemline Therapeutics and Takeda. N.S. reports honoraria from Bristol Myers Squibb/Celgene and Janssen. J.W. reports honoraria from GlaxoSmithKline, Menarini-Stemline Therapeutics, Pfizer, AbbVie, Sanofi, Bristol Myers Squibb, Oncopeptides and Janssen; and research support from Bristol Myers Squibb. F.B. reports honoraria from Bristol Myers Squibb/Celgene and Janssen. C.M.-T. is employed by the University Hospital Heidelberg, and the department receives funding for clinical trials from multiple entities, including Johnson & Johnson. C.H. is employed by, and may own stock in, Johnson & Johnson. C.S. is employed by, and may own stock in, Johnson & Johnson. J. Khan is employed by, and may own stock in, Johnson & Johnson. E.E. is employed by, and may own stock in, Johnson & Johnson. B.D.K. is employed by, and may own stock in, Johnson & Johnson. M.E. reports consultancy for Janssen, Bristol Myers Squibb, Sanofi, Takeda and Pfizer; research funding from Janssen; and honoraria from Janssen, Bristol Myers Squibb, Sanofi and Pfizer. M. Hänel reports honoraria from the Falk Foundation, Kite Pharma, Gilead Sciences, Bristol Myers Squibb, Sobi and Novartis; consultancy for Kite Pharma, Pfizer, Roche, Bristol Myers Squibb, Jazz Pharmaceuticals, GlaxoSmithKline, Takeda, Janssen, Bayer Vital, Sobi, Incyte, Sanofi-Aventis and Amgen; and membership on an entity’s board of directors or advisory committees for Kite Pharma, Pfizer, Roche, Bristol Myers Squibb, Jazz Pharmaceuticals, GlaxoSmithKline, Takeda, Janssen, Bayer Vital, Sobi, Sanofi-Aventis and Amgen. H.S. reports honoraria from Janssen, Bristol Myers Squibb GmbH & Co. KG, Amgen, AbbVie, Stemline Therapeutics, Oncopeptides, AstraZeneca, Sanofi, Genzyme, GlaxoSmithKline, Pfizer and Roche; reports serving in a consulting or advisory role for Pfizer, Janssen Oncology, Sanofi, Oncopeptides, GlaxoSmithKline, Amgen, AbbVie, Bristol Myers Squibb/Celgene, Roche, Genzyme, Stemline Therapeutics and AstraZeneca; and travel accommodations and expenses from Amgen, Bristol Myers Squibb GmbH & Co. KG, Janssen, Pfizer, Stemline Therapeutics and Sanofi. R.T. is currently employed by University Hospital Carl Gustav Carus and reports consultancy for Janssen, Bristol Myers Squibb and Amgen; research funding from Janssen; and honoraria from Janssen, Bristol Myers Squibb, Takeda, GlaxoSmithKline, Gilead Sciences, Amgen, Sanofi, Stemline Therapeutics, Oncopeptides and AbbVie. H.G. reports honoraria from Amgen, Bristol Myers Squibb, Chugai, Sanofi, GlaxoSmithKline, Janssen, Novartis and Pfizer; membership on an entity’s board of directors or advisory committees for Amgen, Bristol Myers Squibb, Adaptive Biotechnologies, Sanofi and Janssen; travel expenses from Amgen, Bristol Myers Squibb, Sanofi, GlaxoSmithKline, Janssen, Novartis and Pfizer; grants and/or provision of investigational medicinal product from Chugai, Sanofi, Array Biopharma/Pfizer, the Dietmar Hopp Foundation, Bristol Myers Squibb/Celgene, Janssen, Johns Hopkins University and Mundipharma GmbH; and research funding from Celgene, Amgen, Bristol Myers Squibb, Sanofi, GlaxoSmithKline, Takeda, GlycoMimetics, Heidelberg Pharma, F. Hoffmann-La Roche, Janssen, Incyte Corporation, Karyopharm, Merck, Millennium Pharmaceuticals, Molecular Partners, MorphoSys AG, Novartis and Pfizer. H.E. reports honoraria from Bristol Myers Squibb, Sanofi, Bristol Myers Squibb/Celgene, Janssen, Amgen, Novartis and Takeda; membership on an entity’s board of directors or advisory committees for Bristol Myers Squibb/Celgene, Janssen, Amgen, Novartis and Takeda; and research funding from Bristol Myers Squibb/Celgene, Janssen, Amgen and Novartis. L.R. reports honoraria from Janssen, Pfizer, GlaxoSmithKline, Bristol Myers Squibb and Amgen and research funding from Skyline Dx and Bristol Myers Squibb.
